15+ Pharmaceutical Industry Trends and Statistics

Fact checked 2025 | 👨‍🎓Cite this article.

The pharmaceutical industry is rapidly evolving, driven by breakthroughs in artificial intelligence (AI), precision medicine, and advanced therapies, such as gene and cell treatments. Future trends emphasize accelerating drug discovery through the use of AI, expanding personalized medicine, and adopting sustainable practices.

These innovations promise faster, more cost-effective development and improved patient outcomes, reshaping how drugs are developed, approved, and delivered globally while navigating regulatory and market complexities.

Global Pharmaceutical Market Size and Growth Trends

Pharmaceutical Industry_1

Fact checked 2025 | 👨‍🎓Cite this stat. This image is copyright free.

Market Valuation and Growth Projections

  • Projected to reach between USD 2.7 trillion and USD 2.83 trillion by 2033, with some forecasts extending to USD 3.5 trillion by 2035.
  • Compound Annual Growth Rate (CAGR) forecasts range from 5.79% to 6.49% for the period 2024-2033/35.
  • The U.S. pharmaceutical market was valued at USD 602 billion in 2023 and is expected to grow to USD 1.09 trillion by 2033 with a CAGR of 6.15%.
  • The pharmaceutical manufacturing market size was USD 589 billion in 2024 and is projected to grow to over USD 1.2 trillion by 2033.

Key Growth Drivers

  • Aging global population
    • The Asia Pacific region is expected to experience the fastest growth due to rising geriatric populations and increasing prevalence of chronic diseases.
  • Chronic and lifestyle diseases
    • Non-communicable diseases (NCDs) account for 71% of global deaths (WHO data).
    • Diseases like cardiovascular disorders, diabetes, cancer, and respiratory conditions significantly drive pharmaceutical demand.
  • Healthcare spending
    • North America held 41.09% market share in 2023, driven by high per capita healthcare expenditure and GDP.
    • North America dominates the pharmaceutical drug delivery market, accounting for a 42.6% share in 2024.
  • Technological innovations
    • AI, precision medicine, digital health, biologics, and biosimilars contribute to market expansion.
    • The COVID-19 pandemic accelerated vaccine and antiviral production, boosting revenues.
  • Pharmerging markets (emerging pharma markets)
    • Valued at USD 1.79 trillion in 2023, expected to grow to USD 4.13 trillion by 2033 at a CAGR of 8.73%.
    • Growth is driven by the demand for generics, the expansion of healthcare infrastructure, and government policies that favor localization. Key countries are India, China, Brazil, Russia, Mexico, South Africa, Indonesia, Turkey.

Pharmaceutical Drug Delivery Market

  • Valued at USD 1,465.2 billion in 2024, projected to reach USD 2,205.5 billion by 2033 with a CAGR of 4.6%.
  • The rising incidence of chronic diseases and technological advances, such as nanotechnology and 3D printing, drive growth.

Historical Evolution of Pharmaceutical Industry Data Practices

Development of Data Collection and Analysis from 20th Century to Present

  • Since 1950, approximately 1,200 new drugs have been approved by the FDA, with the annual output of new drugs remaining essentially constant despite increasing R&D investments.
  • Between 2010 and 2019, the average number of new drug approvals increased to 38 per year, a 60% increase compared to the previous decade.
  • The top 50 pharmaceutical companies collectively spent USD 167 billion on R&D in 2022, underscoring the significant investment in data-driven research.
  • U.S. pharmaceutical R&D spending reached approximately USD 124 billion in 2023, representing about 20% of total industry revenues.
  • The cost of developing a single drug in the U.S. has risen from approximately USD 100 million in the 1970s to over USD 2.6 billion in 2020.

Impact of Digitization

  • Adoption of digital data collection tools increased dramatically:
    • In 2022, 78% of pharmaceutical companies reported significant increases in investments in data visualization tools, up from 34% in 2018.
    • Data visualization initiatives have delivered an average 23% reduction in time-to-market for new drugs.
  • Digital manufacturing data sets now include detailed process data, e.g., a dataset covering 1005 production batches with quality and process data recorded every 10 seconds over several years.
  • U.S. pharmaceutical manufacturing gross output was USD 217.5 billion in 2016, reflecting increased digitization and automation in production processes.

Role of Bioinformatics and Big Data

  • Big data analytics in the pharmaceutical industry now integrates data from multiple sources, including raw material quality, process parameters, clinical trial data, and real-world evidence.
  • IQVIA collects nearly 4 billion prescription claims annually, with data coverage of 90% of retail pharmacies and 75-80% of long-term care pharmacies in the U.S.
  • The MIDAS platform tracks pharmaceutical market data across 77 countries, spanning 12 years of monthly history and covering 693 therapeutic classes.
  • Real-world data from claims and prescriptions enable analysis of 191 million patients in the U.S. since 2006, supporting safety monitoring and outcomes research.

Advances in Drug Discovery and Safety Monitoring

  • AI and machine learning are projected to contribute to 30% of new drug discoveries by 2025, thereby accelerating the screening and identification of targets.
  • Data visualization tools reduce clinical trial data analysis time by 26% and compound screening time by 31%, speeding regulatory submissions by 18%.
  • Despite increasing R&D spending, the number of novel drugs approved annually by the FDA has remained around 40-50 drugs per year since 2008, indicating that the complexity of innovation offsets efficiency gains.

Advances in Drug Development and Therapeutics

Pharmaceutical Industry_3

Fact checked 2025 | 👨‍🎓Cite this stat. This image is copyright free.

Emergence of Biologics

  • The global biologics market size was USD 444.4 billion in 2024 and is projected to reach USD 487 billion in 2025.
  • Forecasted to grow to approximately USD 1,144.2 billion by 2034, with a CAGR of 9.96% from 2025 to 2034.
  • The North American biologics market is estimated at USD 197.9 billion in 2024, growing at a CAGR of 10.08% through 2034.
  • The U.S. biologics market was valued at USD 185.6 billion in 2024 and is projected to reach USD 483.2 billion by 2034.
  • The Biologics CDMO market was valued at USD 24.86 billion in 2025 and is projected to surpass USD 145.49 billion by 2037, growing at a CAGR of 15.6%.
  • The monoclonal antibodies segment is expected to hold a 32.6% market share by 2025, driven by demand for treatments for chronic diseases.
  • U.S. biosimilar approvals reached 73 biosimilars approved and 48 launched by Q1 2025, with 7 new biosimilars launched in Q1 2025.

Personalized Medicine

  • The precision medicine market, closely linked to biologics, is expected to grow at a CAGR of approximately 11-12% from 2023 to 2030.
  • Gene and cell therapies, key components of personalized medicine, have seen an increase in FDA approvals of over 50% between 2018 and 2024.

RNA-Based Therapies

  • The RNA therapeutics market was valued at approximately USD 2.5 billion in 2023 and is projected to grow at a CAGR of 15-18% through 2030.
  • mRNA vaccines and therapies surged post-COVID-19, with over 15 mRNA-based drugs in late-stage clinical trials by 2025.
  • RNA interference (RNAi) therapeutics market is expected to reach USD 1.3 billion by 2027, growing at a CAGR of 20%.

Immuno-Oncology

  • The global immuno-oncology market is valued at USD 85 billion in 2024 and is expected to grow to USD 170 billion by 2030, with a CAGR of around 12%.
  • Checkpoint inhibitors and CAR-T therapies represent over 60% of immuno-oncology revenues.
  • FDA approved over 20 new immuno-oncology therapies between 2018 and 2024.

Influence of Technological Innovations on Drug Pipelines

  • AI-driven drug discovery is expected to contribute to 30% of new drug candidates by 2025, accelerating target identification and screening processes.
  • The use of AI and machine learning reduces clinical trial data analysis time by 26% and compound screening time by 31%.
  • Precision medicine investments increased by over 40% from 2020 to 2024, driving more targeted drug development.
  • The biopharmaceutical market was valued at USD 422.5 billion in 2024 and is expected to reach USD 921.5 billion by 2034, reflecting technology-driven growth.

Regional Market Dynamics and Leading Players

U.S. Pharmaceutical Industry Market Leadership

  • The U.S. pharmaceutical market size was approximately USD 602.19 billion in 2023, with estimates of USD 634.32 billion in 2024 and USD 799.67 billion in 2025 from different sources.
  • Projected to grow at a CAGR of 5.48% to 5.72% from 2024/25 to 2030, reaching between USD 883.97 billion and over USD 1 trillion by 2030.
  • Contributes about 30-40% of global pharmaceutical sales and roughly 45% of worldwide pharmaceutical revenues.
  • U.S. pharmaceutical R&D investment was around USD 102 billion in 2021, with total industry R&D spending estimated at USD 212 billion annually.
  • The industry supports over 800,000 direct jobs and more than 3.2 million indirect jobs in supply chains and related sectors.
  • The North American pharmaceutical market is valued at USD 799.67 billion in 2024 and is projected to reach USD 1,447.20 billion by 2032, with a CAGR of 7.8%.
  • The branded pharmaceutical segment dominated the U.S. market, accounting for a 66.86% revenue share in 2024.
  • Leading U.S. pharmaceutical companies by revenue include:
    • Merck & Co.: USD 64.17 billion (FY 2024 revenue)
    • Pfizer Inc.
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Bristol-Myers Squibb Company

Emerging Markets: India and China

  • Asia Pacific pharmaceutical market is the fastest-growing region, driven largely by China and India.
  • Pharmaceutical intermediates market forecast:
    • Global size of USD 47.30 billion in 2025, projected to reach USD 82.70 billion by 2032, CAGR of 8.3%.
    • North America holds a nearly 40% market share in 2025, but the Asia Pacific shows the fastest growth.
  • India's pharmaceutical market, valued at approximately USD 50 billion in 2024, is expected to grow at a CAGR of 10-12% through 2030 (external knowledge).
  • The Chinese pharmaceutical market is valued at around USD 160 billion in 2024, with an expected CAGR of 7-9% through 2030.
  • India is a global leader in generic drug production, supplying over 20% of global generic medicines.
  • China is a significant player in active pharmaceutical ingredients (APIs), accounting for approximately 40% of the global API market.

Challenges and Future Outlook

Pharmaceutical Industry_2

Fact checked 2025 | 👨‍🎓Cite this stat. This image is copyright free.

Rising Drug Prices

  • U.S. prescription drug spending reached USD 576 billion in 2023, up from USD 558 billion in 2022, a 3.2% increase year-over-year.
  • The GLP-1 drug market, valued at nearly USD 50 billion in 2024, is growing at an annual rate of 11.1%, driven by drugs like semaglutide (Ozempic), which accounted for USD 15.6 billion in U.S. imports in 2024.
  • New U.S. tariffs on pharmaceutical imports from Canada, Mexico, and China threaten to increase drug prices by an estimated 5-7% over the next two years.
  • The Inflation Reduction Act (IRA) is projected to reduce U.S. pharmaceutical revenues by 31% through 2039, potentially resulting in 135 fewer new drug approvals due to cost-benefit shifts.

R&D Investment Trends

  • Global biopharma R&D spending exceeded USD 300 billion annually in 2024, up from USD 275 billion in 2022, representing a 9% increase over the two years.
  • Despite projected revenue growth of 7.5% CAGR through 2030, R&D margins are forecast to decline from 29% in 2020 to 21% by 2030.
  • Phase 1 drug success rates dropped from 10% in 2014 to 6.7% in 2024, increasing development risk and costs.
  • Internal rate of return (IRR) on R&D investments fell to 4.1% in 2024, below the industry’s cost of capital (~8%).
  • Pipeline attrition is rising, with 23,000 drug candidates in development but fewer reaching approval, pressuring budgets, and innovation pipelines.

Future Projections for Market Growth and Innovation

  • Pharmaceutical industry revenue is expected to grow from USD 1.7 trillion in 2024 to over USD 2.8 trillion by 2033, at a CAGR of approximately 5.8%.
  • AI-driven drug discovery is projected to account for 30% of new drugs by 2025, reducing discovery timelines by up to 50% and costs by 20-30%.
  • Gene and cell therapies, antibody-drug conjugates (ADCs), and CAR-T therapies are forecast to grow at double-digit CAGRs, with the CAR-T market expected to reach USD 20 billion by 2030.
  • Mergers and acquisitions (M&A) activity is expected to increase by 77% in 2025, driven by patent expirations and the need to replenish pipelines.
  • The GLP-1 receptor agonists market is expected to grow at an 11.1% CAGR over the next decade, revitalizing interest in small-molecule drugs alongside specialty therapies.

Patient-Centric Approaches

  • Only 29% of healthcare consumers in 2024 reported feeling cared for after healthcare interactions, down from 37% in 2023, highlighting challenges in patient experience.
  • By 2030, the population aged 60 and above is projected to double to 2.1 billion, increasing the demand for personalized and chronic disease therapies.
  • Over 85% of biopharma executives in 2025 are investing in AI and digital tools to enhance supply chain resiliency and patient engagement.
  • Telehealth and remote monitoring adoption increased by 40% between 2021 and 2024, enhancing patient access and facilitating data collection for personalized treatment.

Conclusion

The pharmaceutical industry is being reshaped by data-driven innovation, with AI expected to drive 30% of new drug discoveries by 2025, significantly reducing development costs and timelines. Investment in digital tools is enhancing R&D efficiency, clinical trial inclusivity, and supply chain resilience.

Despite challenges like regulatory pressures and demographic shifts, the sector's focus on sustainability, personalized medicine, and strategic partnerships positions it for sustained growth and improved healthcare outcomes. Embracing these trends will be crucial for industry sustainability and delivering patient-centric solutions in the years to come.

Insights on Pharmaceutical Industry Trends and Statistics

How is AI impacting drug discovery in 2025?

By 2025, AI is expected to drive 30% of new drug discoveries, reducing costs and accelerating development timelines by 25-50%, enabling more personalized treatments.

What is the current size and growth outlook of the pharmaceutical market?

The global pharmaceutical market was valued at over USD 1.7 trillion in 2024 and is projected to surpass USD 2.8 trillion by 2033, growing at a CAGR of around 5.8% to 6.1%.

What are the key technological trends shaping pharma today?

Advances in AI, precision medicine, digital health, and genomics are driving innovation in drug development, clinical trials, and personalized patient care.

How are pharmaceutical companies addressing supply chain challenges?

More than 85% of biopharma executives are investing in AI and digital tools to build resilient, efficient, and sustainable supply chains amid geopolitical and economic uncertainties.

What challenges does the industry face despite growth?

The sector faces patent cliffs, regulatory complexities, cybersecurity risks, and pricing pressures, requiring adaptation to sustain innovation and market competitiveness.

References & Citations:

  1. Always Innovating – Pharmaceutical Industry Facts & Figures
    IFPMA (Dec 2024), Always Innovating – Pharmaceutical Industry Facts & Figures
  2. Big data collection in pharmaceutical manufacturing and its use for product quality predictions
    Janja Žagar, Jurij Mihelič (Mar 2022), Big data collection in pharmaceutical manufacturing and its use for product quality predictions
  3. U.S. pharmaceutical industry – statistics & facts
    Matej Mikulic (Nov 2024), U.S. pharmaceutical industry – statistics & facts
  4. Available IQVIA Data
    IQVIA (2025), Available IQVIA Data
  5. 5 Key Stats: Healthcare Data Visualization in Pharma
    Sarah Lee (Mar 2025), 5 Key Stats: Healthcare Data Visualization in Pharma
  6. Lessons from 60 years of pharmaceutical innovation
    Bernard Munos (Dec 2009), Lessons from 60 years of pharmaceutical innovation
  7. Research and Development in the Pharmaceutical Industry
    David Austin, Tamara Hayford (Apr 2021), Research and Development in the Pharmaceutical Industry
  8. Pharmaceutical Market Size to Surpass USD 2.82 Trillion by 2033
    BioSpace, Press Release by Cervicorn Consulting (Jan 2025), Pharmaceutical Market Size to Surpass USD 2.82 Trillion by 2033
  9. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Formulation, By Age Group, By Route Of Administration, By End Market, By Region- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
    Nova One Advisor (Apr 2025), Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Formulation, By Age Group, By Route Of Administration, By End Market, By Region- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
  10. Pharmaceutical Manufacturing Market Size to Worth USD 1203.95 Billion by 2033
    Straits Research Private Limited – Garner Insights (Jan 2025), Pharmaceutical Manufacturing Market Size to Worth USD 1203.95 Billion by 2033
  11. Pharmaceutical Drug Delivery Market Size, Share, Trends, and Forecast by Route of Administration, Application, End User, and Region, 2025-2033
    IMARC Group (2025), Pharmaceutical Drug Delivery Market Size, Share, Trends, and Forecast by Route of Administration, Application, End User, and Region, 2025-2033
  12. Pharmaceutical Market (By Molecule Type; By Product; By Type; By Disease; By Formulation; By Age Group; By Route of Administration; By End Market) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033
    Vision Research Reports (Mar 2024), Pharmaceutical Market (By Molecule Type; By Product; By Type; By Disease; By Formulation; By Age Group; By Route of Administration; By End Market) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033
  13. Pharmerging Market Size to Hit Around USD 4.13 Trillion by 2033
    BioSpace, Press Release by Nova One Advisor (Sep 2024), Pharmerging Market Size to Hit Around USD 4.13 Trillion by 2033
  14. Global Pharmaceutical Market Size, Share, and COVID-19 Impact Analysis, By Molecule Type (Conventional Drugs (Small Molecules), Biologics & Biosimilars (Large Molecules), and Others), By Product (Branded and Generics), By Type (Prescription and OTC), By Disease (Cancer, Cardiovascular Diseases, Diabetes, Infectious Diseases, Neurological Disorders, Respiratory Diseases, Autoimmune Diseases, Mental Health Disorders, Gastrointestinal Disorders, Women’s Health Issues, Genetic and Rare Genetic Diseases, Dermatological Conditions, Obesity, Renal Diseases, Liver Conditions, Hematological Disorders, Eye Conditions, Infertility, Allergies, and Others), By Route Of Administration (Oral, Parenteral, Topical, Inhalations, and Others), By Formulation (Tablets, Sprays, Injectable, Capsules, and Others), By Age Group (Adults, Children & Adolescents, and Geriatric), By End-User (Hospitals, Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
    Spherical Insights (Jan 2025), Global Pharmaceutical Market Size, Share, and COVID-19 Impact Analysis, By Molecule Type (Conventional Drugs (Small Molecules), Biologics & Biosimilars (Large Molecules), and Others), By Product (Branded and Generics), By Type (Prescription and OTC), By Disease (Cancer, Cardiovascular Diseases, Diabetes, Infectious Diseases, Neurological Disorders, Respiratory Diseases, Autoimmune Diseases, Mental Health Disorders, Gastrointestinal Disorders, Women’s Health Issues, Genetic and Rare Genetic Diseases, Dermatological Conditions, Obesity, Renal Diseases, Liver Conditions, Hematological Disorders, Eye Conditions, Infertility, Allergies, and Others), By Route Of Administration (Oral, Parenteral, Topical, Inhalations, and Others), By Formulation (Tablets, Sprays, Injectable, Capsules, and Others), By Age Group (Adults, Children & Adolescents, and Geriatric), By End-User (Hospitals, Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
  15. Biologics Market Size, Share and Trends 2025 to 2034
    Deepa Pandey, Aditi Shivarkar (Jun 2025), Biologics Market Size, Share and Trends 2025 to 2034
  16. Biologics Market Analysis & Forecast: 2025-2032
    Coherent Market Insights (Feb 2025), Biologics Market Analysis & Forecast: 2025-2032
  17. Biologics CDMO Market – Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
    Radhika Pawar (Apr 2025), Biologics CDMO Market – Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
  18. Biosimilar Market Report
    SAMSUNG BIOEPIS (Q2 2025), Biosimilar Market Report
  19. Biopharmaceutical Market – By Product Type, By Application, By Drug Type, By Manufacturing Type, By Route of Administration, By Prescription Type, By Distribution Channel – Global Forecast 2025 – 2034
    Mariam Faizullabhoy, Gauri Wani (Apr 2025), Biopharmaceutical Market – By Product Type, By Application, By Drug Type, By Manufacturing Type, By Route of Administration, By Prescription Type, By Distribution Channel – Global Forecast 2025 – 2034
  20. Pharmaceutical Market Size Expected to Reach USD 3,033.21 Bn by 2034
    Precedence Statistics (Feb 2025), Pharmaceutical Market Size Expected to Reach USD 3,033.21 Bn by 2034
  21. The U.S. Pharmaceuticals Industry in 2025: Innovation, Challenges, and Shifting Dynamics
    Brady McKinney (Feb 2025), The U.S. Pharmaceuticals Industry in 2025: Innovation, Challenges, and Shifting Dynamics
  22. U.S. Pharmaceutical Statistics
    Yellow Bus ABA (Mar 2025), U.S. Pharmaceutical Statistics
  23. Pharmaceutical Intermediates Industry Report 2025: Market to worth $82.70 Billion by 2032 – Driven by Surge in Global Pharma Expenditure
    BioSpace, Press Release by Coherent Market Insights (May 2025), Pharmaceutical Intermediates Industry Report 2025: Market to worth $82.70 Billion by 2032 – Driven by Surge in Global Pharma Expenditure
  24. U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Biologics & Biosimilars, Conventional Drugs), By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 – 2030
    Grand View Research (2025), U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Biologics & Biosimilars, Conventional Drugs), By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 – 2030
  25. North America Pharmaceuticals Market Size, Share & Industry Analysis, By Type (Drugs {Oncology, Diabetes, Infectious Diseases, Cardiology, Neurology, Respiratory, Hypertension, Anti-Obesity, Dermatology, Ophthalmology, and Others} and Vaccines {Viral Diseases and Bacterial Diseases}), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032
    Fortune Business Insights (Jun 2025), North America Pharmaceuticals Market Size, Share & Industry Analysis, By Type (Drugs {Oncology, Diabetes, Infectious Diseases, Cardiology, Neurology, Respiratory, Hypertension, Anti-Obesity, Dermatology, Ophthalmology, and Others} and Vaccines {Viral Diseases and Bacterial Diseases}), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032
  26. Pharma 50: The top pharma companies in the world for 2025
    Drug Discovery & Development (2025), Pharma 50: The top pharma companies in the world for 2025
  27. Breakthroughs or bottlenecks? Pharma industry outlook, trends and strategies for 2025
    Bill Coyle , Rahul Pathak , Raluca Cenusa, Divyata Manvati (Jan 2025), Breakthroughs or bottlenecks? Pharma industry outlook, trends and strategies for 2025
  28. Next in pharma 2025: The future is now
    PwC Insights (Jan 2025), Next in pharma 2025: The future is now
  29. How 2025 can be a pivotal year of progress for pharma
    Paul Hudson (Jan 2025), How 2025 can be a pivotal year of progress for pharma
  30. Biopharma R&D Faces Productivity And Attrition Challenges In 2025
    Daniel Chancellor (Jan 2025), Biopharma R&D Faces Productivity And Attrition Challenges In 2025
  31. 2025 life sciences outlook
    Pete Lyons, Todd Konersmann, Leena Gupta, Darshan Gosalia (Dec 2024), 2025 life sciences outlook
  32. TOP Challenges Facing the Pharmaceutical Industry in 2025
    Viseven (Jan 2025), TOP Challenges Facing the Pharmaceutical Industry in 2025
  33. 2025 Preview: What does the year ahead hold for pharma?
    Evaluate, a Norstella Company (Jan 2025), 2025 Preview: What does the year ahead hold for pharma?